Invex Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Invex Therapeutics non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Duthy	Executive Director	4.1yrs	AU$357.23k	0.38% A$ 25.7k
David McAuliffe	Non-Executive Chairman	5.7yrs	AU$57.24k	4.46% A$ 301.5k
David Wheeler	Non-Executive Director	less than a year	AU$36.17k	Nessun dato

4.1yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IXC sono considerati esperti (durata media dell'incarico 4.1 anni).

Invex Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Invex Therapeutics Ltd, Annual General Meeting, Nov 26, 2024

No independent directors

Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director

Less than half of directors are independent

Invex Therapeutics Ltd, Annual General Meeting, Nov 28, 2023

Invex Therapeutics Ltd Announces Board Changes

Recent updates

Invex Therapeutics Ltd, Annual General Meeting, Nov 26, 2024

No independent directors

New major risk - Market cap size

Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director

Less than half of directors are independent

Invex Therapeutics Ltd, Annual General Meeting, Nov 28, 2023

Invex Therapeutics Ltd Announces Board Changes

New major risk - Market cap size

Invex Therapeutics Ltd to Report Q4, 2022 Results on Jan 25, 2023

Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA

Invex Therapeutics Ltd Announces Approval to Commence the IIH EVOLVE Phase III Clinical Trial Received from the New Zealand Medicines and Medical Devices Safety Authority

Invex Therapeutics Ltd Announces First Patient Randomised in Iih Evolve Phase Iii Trial

Less than half of directors are independent

Invex Therapeutics Ltd to Report Q1, 2023 Results on Oct 27, 2022

Less than half of directors are independent

Invex Therapeutics Ltd Announces the Receipt of A Second Human Research Ethics Committee Approval to Commence the IIH EVOLVE Phase III Clinical Trial in Australia

Invex Therapeutics Ltd, Annual General Meeting, Nov 22, 2022

Less than half of directors are independent

Invex Therapeutics Ltd Announces the Receipt of Human Research Ethics Committee Approval and Clinical Trial Notification

Invex Therapeutics Ltd to Report Q4, 2022 Results on Jul 06, 2022

Invex Therapeutics Ltd Receives MHRA Approval to Commence IIH EVOLVE Phase III Clinical Trial in the UK

Less than half of directors are independent

Invex Therapeutics Ltd to Report Q1, 2022 Results on Apr 19, 2022

Invex Therapeutics Ltd Provides Formulation and Manufacturing Update

United States Patent and Trademark Office Grants Trademark for Invex Therapeutics Ltd's Presendin

Invex Therapeutics Ltd Appoints Megan Baldwin as an Independent Non-Executive Director

New 90-day high: AU$0.90

Invex Therapeutics Ltd Appoints Tom Duthy as an Executive Director, Effective 1 October 2020

Full year earnings released - AU$0.06 loss per share

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media